Other
Oligometastatic Disease
0
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
Oligometastatic Disease is an early-stage landscape with 0 programs across 1 company. The most active players are Robert Olson.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
3
clinical trials
Terminated1 · 33%
Not yet recruiting1 · 33%
Recruiting1 · 33%
Clinical Trials
Trial Activity
Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation
Terminated·—·Phase 2·NCT01345539·24 enrolled
Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease
Not yet recruiting·—·Phase 3·NCT06141070·240 enrolled
Single vs. Multiple Fraction Non-Inferiority Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligo-metastases/Progression: SIMPLIFY-SABR-COMET
Recruiting·—·Preclinical·NCT05784428·598 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)